Despite high initial response rates in B-cell precursor leukemia and lymphoma, anti-CD19 CAR T-cell therapy can lack long-term efficacy due to multiple factors including limited CAR T-cell proliferation and persistence (3, 27). Here, CD19 is linked to lymphoma.